化疗致恶心、呕吐的机制及治疗研究进展

被引：30

作者：

徐红丽 ^{[1
]}

赵建武 ^{[2
]}

机构：

[1] 遵义医学院

[2] 贵州省人民医院

来源：

临床合理用药杂志 | 2016年 / 9卷 / 10期

关键词：

化疗; 恶心呕吐; 治疗; 机制;

D O I：

10.15887/j.cnki.13-1389/r.2016.10.104

中图分类号：

R730.53 [化学（药物）疗法];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

<正>在化疗所有副反应中,最常见的是消化道反应,而其中最常见的是恶心、呕吐。这些反应使患者感到痛苦,严重者可引起自身代谢失调、电解质紊乱等。患者常常因严重的恶心呕吐反应推迟化疗,甚至拒绝下一步化疗,从而影响治疗的疗效。在过去几十年中,恶心、呕吐反应的处理有较大提高,使患者痛苦得到极大减轻,进而使化疗达到一定的目的,但目前对于化疗引起恶心、呕吐反应的机制尚未明确。1定义与分类1.1恶心及呕吐定义恶心是指上腹部的不适感,可伴随迷

引用

页码：174 / 175

页数：2

共 11 条

[1]

诊断学.[M].陈文彬;潘祥林主编;.人民卫生出版社.2004,

[2]

Palonosetron exhibits higher total control rate compared to first‑generationserotonin antagonists and improves appetite in delayed‑phase chemotherapy‑inducednausea and vomiting.[J].Hiroki Ueda;Chigusa Shimono;Tomoyasu Nishimura;Megumi Shimamoto;Hiroki Yamaue.Molecular and Clinical Oncology.2014, 3

[3]

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study [J].

Mizukami, Naomi ;

Yamauchi, Masanori ;

Koike, Kazuhiko ;

Watanabe, Akihiko ;

Ichihara, Koji ;

Masumori, Naoya ;

Yamakage, Michiaki .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2014, 47 (03) :542-550

[4]

Management of Chemotherapy-Induced Nausea and Vomiting.[J].Rudolph M. Navari.Drugs.2013, 3

[5]

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial [J].

Grunberg, Steven M. ;

Rolski, Janusz ;

Strausz, Janos ;

Aziz, Zeba ;

Lane, Stephen ;

Russo, Mark W. ;

Wissel, Paul ;

Guckert, Mary ;

Wright, Oliver ;

Herrstedt, Jorn .

LANCET ONCOLOGY, 2009, 10 (06) :549-558

[6]

Brain Fos expression during 48 h after cisplatin treatment: Neural pathways for acute and delayed visceral sickness.[J].Charles C. Horn;Marc Ciucci;Arun Chaudhury.Autonomic Neuroscience: Basic and Clinical.2006, 1

[7]

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial [J].

Hickok, JT ;

Roscoe, JA ;

Morrow, GR ;

Bole, CW ;

Zhao, HW ;

Hoelzer, KL ;

Dakhil, SR ;

Moore, T ;

Fitch, TR .

LANCET ONCOLOGY, 2005, 6 (10) :765-772

[8]

Delayed emesis: moderately emetogenic chemotherapy [J].

Roila, F ;

Warr, D ;

Clark-Snow, RA ;

Tonato, M ;

Gralla, RJ ;

Einhorn, LH ;

Herrstedt, J .

SUPPORTIVE CARE IN CANCER, 2005, 13 (02) :104-108

[9]

Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.[J].Karin Jordan;Christoph Kasper;Hans-Joachim Schmoll.European Journal of Cancer.2004, 2

[10]

New treatment options for chemotherapy-induced nausea and vomiting [J].

Hesketh, PJ .

SUPPORTIVE CARE IN CANCER, 2004, 12 (08) :550-554

← 1 2 →